Vertex Pharmaceuticals Inc (VRTX) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $480.13
• Market Cap: $122.69B
• P/E Ratio: 31.55
• EPS: $15.31
• 52-Week High: $519.68
• 52-Week Low: $362.50

Market Sentiment

Vertex Pharmaceuticals Inc currently has a Bullish sentiment score of 0.20.

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals Inc. is a premier biopharmaceutical company based in Boston, Massachusetts, recognized for its pioneering development and commercialization of breakthrough therapies for serious diseases, most notably cystic fibrosis (CF). With an impressive array of approved therapies powered by its proprietary scientific innovations, Vertex has significantly changed the treatment paradigm for CF patients and remains steadfast in addressing critical unmet medical needs. The company is ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Vertex Pharmaceuticals Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does VRTX pay dividends?

Vertex Pharmaceuticals Inc (VRTX) does not currently pay a regular dividend.

What is VRTX's P/E ratio?

Vertex Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 31.55.

What is VRTX's market cap?

Vertex Pharmaceuticals Inc (VRTX) has a market capitalization of $122.69B with a current stock price of $480.13.